Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Bristol-Myers Squibb
(NY:
BMY
)
54.32
-1.45 (-2.60%)
Official Closing Price
Updated: 7:00 PM EDT, Nov 1, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Bristol-Myers Squibb
< Previous
1
2
3
4
5
6
7
8
9
...
65
66
Next >
What the Options Market Tells Us About Bristol-Myers Squibb
July 01, 2024
Via
Benzinga
Treasure Hunt: 3 Small-Cap Stocks Wall Street Hasn’t Discovered Yet
June 30, 2024
Undiscovered small-cap stocks hold the greatest potential for creating investor wealth as they can take off at a moment's notice.
Via
InvestorPlace
Is Bristol Myers Squibb Stock a Buy?
June 28, 2024
Does Bristol Myers have the potential to be a market-beating stock?
Via
The Motley Fool
Novo Nordisk Buys 2seventy's Hemophilia A Program, Divestiture Supports Exclusive Focus On Abecma
June 27, 2024
2seventy Bio finalized an asset purchase agreement with Novo Nordisk involving the Hemophilia A program and in vivo gene editing technology. The 2seventy bio team will join Novo Nordisk, focusing on...
Via
Benzinga
You’ve Been Warned! 3 Pharma Stocks to Buy Now or Regret Forever.
June 27, 2024
Pharmaceutical stocks can be considered risky, but when their trials get approved by FDA, the stock can go to the moon.
Via
InvestorPlace
Exposures
Product Safety
What the Options Market Tells Us About Bristol-Myers Squibb
June 26, 2024
Via
Benzinga
Bristol-Myers Squibb Stock Price Forecast: Is The Downtrend Finally Over?
June 19, 2024
Technical analysis suggests short-term support at $39.90; potential recovery to $56.
Via
Talk Markets
This Is What Whales Are Betting On Bristol-Myers Squibb
June 18, 2024
Via
Benzinga
FDA Approves Bristol Myers Squibb's Combination Therapy For Colorectal Cancer Patients With Certain Type Of Gene Mutation
June 24, 2024
The FDA granted accelerated approval to Bristol Myers Squibb's Krazati (adagrasib) with cetuximab for adult patients with KRASG12C-mutated advanced or metastatic colorectal cancer.
Via
Benzinga
Exposures
Product Safety
7 Dividend Stocks to Buy Now: June 2024
June 23, 2024
These dividend stocks to buy now will reward investors with income now and growth as the market breadth expands.
Via
InvestorPlace
AbbVie Inc. Dividend Stock Analysis - Saturday, June 22
June 22, 2024
Here are some highlights from a detailed, quantitative analysis AbbVie Inc. stock. Let's take a closer look at various factors, such as the stock's value and dividend.
Via
Talk Markets
S&P 500 Earnings Dashboard 24Q1 - Saturday, June 22
June 22, 2024
Of the 498 companies in the S&P 500 that have reported earnings to date for 24Q1, 78.7% reported above analyst expectations. This compares to a long-term average of 66%.
Via
Talk Markets
Topics
Stocks
Exposures
US Equities
3 No-Brainer Stocks to Buy for Under $100 Right Now
June 22, 2024
You won't need much money to start investing in these great stocks.
Via
The Motley Fool
3 High-Yield Dividend Stocks Near Their 52-Week Lows to Buy and Hold
June 22, 2024
The pharmaceutical industry giants offer reliable profit growth and above-average dividend yields.
Via
The Motley Fool
Bristol Myers Squibb Announces U.S. FDA Accelerated Approval of KRAZATI® (adagrasib) in Combination with Cetuximab for Adult Patients with Previously Treated KRAS G12C-Mutated Locally Advanced or Metastatic Colorectal Cancer (CRC)
June 21, 2024
From
Bristol Myers Squibb
Via
Business Wire
Gilead Sciences Faces Wall Street Speculation About Obesity Drugs Despite Focus On Liver Treatments
June 21, 2024
Gilead Sciences faces Wall Street speculation about its potential in the obesity drug market despite its focus on liver treatments.
Via
Benzinga
European Medicines Agency Validates Bristol Myers Squibb’s Application for Subcutaneous Nivolumab
June 21, 2024
From
Bristol Myers Squibb
Via
Business Wire
German Drug Developer Evotec Seeks Adviser Input As Takeover Concerns Mount
June 20, 2024
Evotec consults defense advisers following a significant share price decline, raising concerns about a potential takeover.
Via
Benzinga
Bristol Myers Squibb to Report Results for Second Quarter 2024 on July 26, 2024
June 20, 2024
From
Bristol Myers Squibb
Via
Business Wire
3 Warren Buffett Stocks to Buy Now: June 2024
June 19, 2024
If you have a long-term view of the market, it’s a good time to look for some Warren Buffett stocks to buy now.
Via
InvestorPlace
10 Health Care Stocks Whale Activity In Today's Session
June 19, 2024
Via
Benzinga
Bristol Myers Squibb Elects Michael R. McMullen to Board of Directors
June 18, 2024
From
Bristol Myers Squibb
Via
Business Wire
Better High-Yield Dividend Stock: Pfizer vs. Bristol Myers Squibb
June 18, 2024
These two pharma stocks are beloved by income investors.
Via
The Motley Fool
Bristol Myers Squibb Announces Dividend
June 18, 2024
From
Bristol Myers Squibb
Via
Business Wire
7 Breakthrough Biotech Stocks for a Shot of Portfolio Adrenaline
June 17, 2024
With biotech stocks enjoying a permanently relevant narrative, investors should focus on these compelling opportunities.
Via
InvestorPlace
Acute Myeloid Leukemia Market Size Expected to Reach $2.97 Billion By 2029 as Clinical Trials Increase
June 17, 2024
EQNX::TICKER_START (NYSE:ATNM),(NASDAQ:BPTH),(NASDAQ:LGVN),(NASDAQ:SLS),(NYSE:BMY) EQNX::TICKER_END
Via
FinancialNewsMedia
3 High-Yield S&P 500 Dividend Stocks Down More Than 25% to Buy Now and Hold for at Least a Decade
June 15, 2024
Their prices might not be done falling, but you can count on the dividends they distribute to continue rising steadily.
Via
The Motley Fool
Topics
Stocks
Exposures
US Equities
Acute Myeloid Leukemia Market Size Expected to Reach $2.97 Billion By 2029 as Clinical Trials Increase
June 17, 2024
From
FN Media Group LLC
Via
GlobeNewswire
3 High-Yield Dividend Stocks for Income Now and Growth Later
June 14, 2024
Buying high-yield dividend stocks at a low price today gives you current income with the opportunity for growth when interest rates come down later this year
Via
MarketBeat
Topics
Economy
Exposures
Interest Rates
U.S. Food and Drug Administration Approves Augtyro™ (repotrectinib), a Next-Generation Tyrosine Kinase Inhibitor (TKI), for the Treatment of Patients with NTRK-Positive Locally Advanced or Metastatic Solid Tumors
June 13, 2024
From
Bristol Myers Squibb
Via
Business Wire
< Previous
1
2
3
4
5
6
7
8
9
...
65
66
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.